Drug target discovery by pharmacogenetics: mutations in the melanocortin system and eating disorders.


The identification of the genetic defect underlying the obese phenotype of the viable yellow mouse, ectopic overexpression of the agouti protein which acts as antagonist at the melanocortin-4 receptor, together with the demonstration that the brain melanocortin system was one major downstream effector pathway of leptin signaling has put forward melanocortin… (More)


  • Presentations referencing similar topics